Mary Wilson
Well-known member
This article is a preprint and has not been certified by peer review
Posted February 11, 2021
doi: https://doi.org/10.1101/2021.02.11.430787
Markus Hoffmann, Prerna Arora, R?diger Gro?, Alina Seidel, Bojan H?rnich, Alexander Hahn, Nadine Kr? ger, Luise Graichen, Heike Hofmann-Winkler, Amy Kempf, Martin Sebastian Winkler, Sebastian Schulz, Hans-Martin J?ck, Bernd Jahrsd?rfer, Hubert Schrezenmei er, Martin M?ller, Alexander Kleger, Jan M?nch, Stefan P?hlmann
Abstract
SUMMARY
The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the COVID-19 pandemic. However, recently emerged SARS-CoV-2 variants B.1.1.7 (UK), B.1.351 (South Africa) and B.1.1.248 (Brazil) harbor mutations in the viral spike (S) protein that may alter virus-host cell interactions and confer resistance to inhibitors and antibodies. Here, using pseudoparticles, we show that entry of UK, South Africa and Brazil variant into human cells is susceptible to blockade by entry inhibitors. In contrast, entry of the South Africa and Brazil variant was partially (Casirivimab) or fully (Bamlanivimab) resistant to antibodies used for COVID-19 treatment and was less efficiently inhibited by serum/plasma from convalescent or BNT162b2 vaccinated individuals. These results suggest that SARS-CoV-2 may escape antibody responses, which has important implications for efforts to contain the pandemic.
Full Text:
https://www.biorxiv.org/content/10.1101/2021.02.11.430787v1.full
Posted February 11, 2021
doi: https://doi.org/10.1101/2021.02.11.430787
Markus Hoffmann, Prerna Arora, R?diger Gro?, Alina Seidel, Bojan H?rnich, Alexander Hahn, Nadine Kr? ger, Luise Graichen, Heike Hofmann-Winkler, Amy Kempf, Martin Sebastian Winkler, Sebastian Schulz, Hans-Martin J?ck, Bernd Jahrsd?rfer, Hubert Schrezenmei er, Martin M?ller, Alexander Kleger, Jan M?nch, Stefan P?hlmann
Abstract
SUMMARY
The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the COVID-19 pandemic. However, recently emerged SARS-CoV-2 variants B.1.1.7 (UK), B.1.351 (South Africa) and B.1.1.248 (Brazil) harbor mutations in the viral spike (S) protein that may alter virus-host cell interactions and confer resistance to inhibitors and antibodies. Here, using pseudoparticles, we show that entry of UK, South Africa and Brazil variant into human cells is susceptible to blockade by entry inhibitors. In contrast, entry of the South Africa and Brazil variant was partially (Casirivimab) or fully (Bamlanivimab) resistant to antibodies used for COVID-19 treatment and was less efficiently inhibited by serum/plasma from convalescent or BNT162b2 vaccinated individuals. These results suggest that SARS-CoV-2 may escape antibody responses, which has important implications for efforts to contain the pandemic.
Full Text:
https://www.biorxiv.org/content/10.1101/2021.02.11.430787v1.full